RxDoctor Payments Data

Mohammed Mirza, MD

Psychiatry · Lees Summit, MONPI 1710067822

Payments from drug & device makers

$11,654in general payments, 2019–2025

Across 685 payments — averaging $17.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
  • AbbVie$2K
  • Otsuka America Pharmaceutical, Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$989
  • Johnson & Johnson$972
  • Lundbeck LLC$740
  • plus $5K from 34 others

What the payments were for

  • Food & beverage$11,600100%
  • Education$540%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,654 in reported general payments places this provider in the 85th percentile of 680 psychiatry providers in Missouri.

See all psychiatry providers in Missouri

Medicare billing

Part B allowed, 2024
$92,013
Medicare patients
155
Services billed
714

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine17$138,488
RexultiBrexpiprazole48$79,045
VraylarCariprazine Hcl33$49,875
CaplytaLumateperone Tosylate18$33,623
TrintellixVortioxetine Hydrobromide31$19,182
Oxcarbazepine253$16,150
Divalproex Sodium ErDivalproex Sodium149$12,274
Quetiapine Fumarate558$11,289
Lurasidone Hcl95$10,368
Aripiprazole160$9,990
XanaxAlprazolam12$9,584
Duloxetine Hcl208$9,566
Risperidone282$6,779
VyvanseLisdexamfetamine Dimesylate17$6,475
Chlorpromazine Hcl54$5,845

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$989$138,48817 claims
Otsuka America Pharmaceutical, Inc.Rexulti$1,078$79,04548 claims
AbbVieVraylar$1,506$49,87533 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$1,742$33,62318 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$363$25,65748 claims
Almatica Pharma LLCSertraline Hcl$70$2,205314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 680 psychiatry providers in Missouri.

Other psychiatry in Lees Summit

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →